Please educate me because what I see is a stock that peaked on March 5 at $21.13/share and now sits at $12.75/share -- a loss of 40%.
My argument in my post was that there doesn't seem to be support at any level, and the 40% decline in RGLS supports that thesis. Further, my argument was that the manipulation of Biotech stocks was irrelevant of fundamentals, outlook, prospects, etc., and was not stock specific. So please, fill in the missing blanks that shows me there IS in fact support for stocks like RGLS, and maybe it is going up instead of 40% down.
I am open to learn, so have at it.
That is the real underlying value. It's as if there was a blip on the Apple Watch. It is such a tiny part of their sales, it would be inconsequential, although headline-grabbing to be sure. This is much ado about nothing.
Not only that, I wouldn't hesitate to buy LL products/flooring and put them in my own home - and sleep on them face down!
I stand by my call that ISIS is at a bottom. A week/month/year from now it will be higher, much higher. A year from now - DOUBLE.
Really? I thought I was looking kinda smart ...
I think people are wary, nothing more. They are careful, but therein lies the problem. The slam story by the media-junkie was very damaging because it cast a lot of doubt Nd raised questions that are very hard for anyone to answer.
A lot like a school principal accused of inappropriate behavior - it is such a sticky situation, the allegation alone is damaging. Even if completely unfounded.
While I'm not sure what triggered the sell off to begin with, they posted good numbers and a nice Quarter. Should rebound from here well.
Ignore those that pretend LL is way overvalued, because clearly it is not. Only a small percentage of the flooring is in question. I will wait solely based on the DOJ probe because nothing this government administration touches - is good. The only question is how bad it will be and for how long.
Ideally, the government will be thorough and come back and say LL is squeaky clean. That would boost shares 50% or more overnight. But it will take time for that to happen, and during that time, the shorts will have their way.
But shorts should be very very careful. A strategy change by the company, or govt vindication could cause a major gap up instantly, and there will be no recovery for shorts then.
While the DOJ probe may ultimately vindicate LL and prove conclusively they are clean, nothing much good ever comes with these kind of dealings with the government. Very dangerous and expensive.
Good luck to LL longs. I'll check back later to buy on a dip.
This appears to be the bottom. I never thought this stock would ever dip below $60 again, this should rebound from here.
I guess it isn't that hard to pass a stationary object that isn't making any progress. At least with the CEO replaced there is some hope they can move forward.
Merck, Pfizer, others, all beating to the upside, but a massive selloff across the Biotech sector, from 5-20% gone in a few days for no reason, other than market manipulation.
Wasn't Obama going to clean all this #$%$ up?
This is nothing more than market manipulation, with all biotechs selling off, then a big surge coming in May to return them back to where they were before the artificial pullback. ISIS looks as good as ever.
Uh, ok, not sure what your post has to do with my post ... But OK.
Prince - go easy on him - that short position must be absolutely KILLING him.
You whine about "not one safe drug in 27 years" revealing all your IDs at once that have the same clueless mantra. They do have proven safe drugs - maybe not by your standards - but by FDA standards and regular medical standards.
Is your argument about the stock so very weak you must resort to childish name calling? You are another one I would absolutely LOVE to meet face to face - though cowards won't meet.
You know, perhaps you and I should meet face to face. People are much more polite when face to face.
I think this one is ripe for a buyout / takeover. It will be the buyout nobody saw coming. Though it isn't that hard to see that the high earnings growth rate of nearly 100% year over year would boost any acquirers balance sheet and improve their financial picture. At under $1B market cap, there are a lot of acquirers who can easily afford it.